Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
26.09. | Aptamer Group PLC - Investor Event and Presentation | 1 | RNS | ||
11.09. | Aptamer and Metir agree contract for detection of waterborne parasite | 4 | Alliance News | ||
11.09. | Aptamer Group signs development contract with Metir | 1 | Sharecast | ||
APTAMER GROUP Aktie jetzt für 0€ handeln | |||||
11.09. | Aptamer Group PLC - New contract with Metir plc | 1 | RNS | ||
11.09. | Metir PLC - New Contract with Aptamer Group | - | RNS | ||
09.09. | Director dealings: Aptamer chairman raises stake | 3 | Sharecast | ||
09.09. | Aptamer Group PLC - Notification of dealings by a director/PDMR | 1 | RNS | ||
03.09. | Aptamer Group Partners with Invizius to Develop Next-Gen Complement System Therapies | 3 | Contract Pharma | ||
02.09. | Aptamer Group PLC - Therapeutic development agreement with Invizius | 1 | RNS | ||
27.08. | Aptamer launches biomarker discovery service to expand revenue base | 1 | The Armchair Trader | ||
27.08. | Aptamer Group PLC - Biomarker Discovery Service Launch | - | RNS | ||
22.08. | Aptamer shares jump amid progress in enzyme inhibitor licensing deals | 2 | Alliance News | ||
22.08. | Aptamer reports progress across enzyme modulation pipeline | 6 | Sharecast | ||
22.08. | Aptamer Group PLC - Update on licensing and development progress | - | RNS | ||
19.08. | Aptamer Group PLC - Exercise of warrants | - | RNS | ||
18.08. | Aptamer secures contract extension with 'top five global pharma' partner | 1 | Sharecast | ||
18.08. | UK Stock Market News: Aptamer, MicroSalt, HICL | 1 | The Armchair Trader | ||
18.08. | Aptamer Group PLC - Contract extension with global pharma partner | 2 | RNS | ||
08.08. | Aptamer Group PLC - Investor Technical Webinar | 1 | RNS | ||
04.08. | AIM Market Roundup: Westmount Energy, Aptamer, Europa Oil & Gas | 1 | The Armchair Trader |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
RECURSION PHARMACEUTICALS | 5,520 | 0,00 % | Looking for the Next Big Pop? Here's Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce | ||
TAYSHA GENE THERAPIES | 4,880 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome | Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized... ► Artikel lesen | |
QIAGEN | 39,470 | +0,71 % | ROUNDUP/Aktien Frankfurt Eröffnung: Moderate Verluste - Richtungssuche | FRANKFURT (dpa-AFX) - Nach den leichten Gewinnen vom Vortag haben die Anleger am deutschen Aktienmarkt am Donnerstag wieder etwas auf die Bremse getreten. "Die Richtungssuche geht weiter", konstatierte... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 44,180 | +2,72 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
EVOTEC | 6,612 | +4,36 % | Evotec: Aktie in Problemen? - Aixtron, Circus, Commerzbank, Gerresheimer und Rheinmetall im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 7,460 | 0,00 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
VERA THERAPEUTICS | 29,190 | +1,39 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
BIONTECH | 89,10 | +2,36 % | BioNTech fürchtet neue Zölle, Eli Lilly tritt auf die Bremse, Daimler Truck verliert trotz Rüstungsfantasien und auch Siemens Healthineers zittert | Erst vor wenigen Tagen kam die für viele erleichternde Nachricht, dass eine Zollvereinbarung zwischen den USA und der EU rückwirkend zum 1. August greift, was vor allem Autobauern ein wenig Luft zum... ► Artikel lesen | |
STRUCTURE THERAPEUTICS | 26,620 | +2,27 % | Aktien New York: Weitere Rekorde - auch dank Nvidia und Apple | NEW YORK (dpa-AFX) - Die US-Börsen haben am Montag nach einem verhaltenen Start ihre Rekordjagd fortgesetzt. Auch dank deutlicher Kursgewinne der Schwergewichte Nvidia und Apple verzeichnete der Leitindex... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 37,470 | 0,00 % | What Analysts Are Saying About Kiniksa Pharmaceuticals Stock | ||
APOGEE THERAPEUTICS | 39,610 | 0,00 % | Apogee Therapeutics stock initiated at Outperform by RBC Capital | ||
DISC MEDICINE | 65,86 | -1,86 % | Disc Medicine Inc: Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP) | Disc is seeking accelerated approval and priority review of its NDA submissionFDA decision to accept and file the NDA for review occurs within 60 days of submission WATERTOWN, Mass., Sept. 30,... ► Artikel lesen | |
TANGO THERAPEUTICS | 7,690 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen | |
ARCUTIS BIOTHERAPEUTICS | 21,250 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 | ||
SUMMIT THERAPEUTICS | 20,870 | 0,00 % | Summit Therapeutics: HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025 | Ivonescimab in Combination with Chemotherapy in HARMONi-6, Conducted by Akeso in China, is the First Known Regimen to Achieve a Statistically Significant Clinically Meaningful Improvement in PFS... ► Artikel lesen |